The FDA has approved Firvanq (vancomycin hydrochloride) oral liquid therapy to treat Clostridium difficile-associated diarrhea and enterocolitis resulting from Staphylococcus aureus.
Indications: Firvanq (vancomycin hydrochloride) for oral solution, is approved for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.
Dosage/administration: Firvanq will be available in 25 mg/mL and 50 mg/mL strengths in convenient 150 mL and 300 mL sizes. It is designed to be easy to use and has the potential to be a cost-effective alternative to existing vancomycin therapies.
CutisPharma announces FDA approval of FIRVANQ. [news release]. Wilmington, MA: CutisPharma; January 29, 2018. http://cutispharma.com/cutispharma-announces-fda-approval-firvanq/. Accessed January 30, 2018.
This Week's Must Reads
IDSA Updates Seasonal Influenza Guidelines, Clin Infect Dis; ePub 2018 Dec 19; Uyeki, et al
Efficacy of Cell-Cultured & Egg-Based Influenza Vaccines, J Infect Dis; ePub 2018 Dec 18; Izurieta, et al
Prevention of Influenza Hospitalization in US Adults, J Infect Dis; ePub 2018 Dec 14; Ferdinands, et al
Clinical & Virologic & Characteristics of Zika Virus Infection, Open Forum Infect Dis; ePub 2018 Dec 19; El Sahly, et al
Importations of Measles Virus in the US, J Infect Dis; ePub 2018 Dec 9; Lee, et al
Must Reads in Antimicrobial-resistant infections
PCT-Guided Antibiotic Therapy in LRTIs, Open Forum Infect Dis; ePub 2018 Dec 3; Townsend, et al
Pyrosequencing for the Clinical Management of TB, Clin Infect Dis; ePub 2018 Nov 1; Lowenthal, et al
GI Microbiota Disruption with CRPA in ICU Patients, Clin Infect Dis; ePub 2018 Nov 1; Pettigrew, et al
New IDSA Guideline for Management of OPAT, Clin Infect Dis; ePub 2018 Nov 13; Norris, et al
OPAT Outcomes in SNFs vs HHCs, Open Forum Infect Dis; ePub 2018 Oct 24; Townsend, et al